QSAM Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)

3 Months Ended

Mar. 31, 2019

Schedule of Liabilities Measured at Fair Value

The following tables set forth the Company’s consolidated financial assets and liabilities measured at fair value by level within the fair value hierarchy at March 31, 2019 and December 31, 2018. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

	Fair value at
	March 31, 2019		Level 1		Level 2		Level 3
Convertible Bridge Notes	$	2,850,000	$	-	$	-	$	2,850,000
Total	$	2,850,000	$	-	$	-	$	2,850,000

	Fair value at
	December 31, 2018		Level 1		Level 2		Level 3
Convertible Bridge Notes	$	2,960,000	$	-	$	-	$	2,960,000
Total	$	2,960,000	$	-	$	-	$	2,960,000

Schedule of Reconciliation of Level 3 Conversion Option Liability

The following tables present a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis that use significant unobservable inputs (Level 3) and the related realized and unrealized gains (losses) recorded in the consolidated statement of operations during the periods.

	Three Months Ended March 31, 2019
Fair value, December 31, 2018	$	2,960,000
Issuances of debt		-
Accrued interest		138,938
Conversions of debt and accrued interest to shares of common stock		-
Amortization of debt issuance costs		1,250
Net unrealized gain on convertible bridge notes		(250,188	)
Fair value, March 31, 2019	$	2,850,000

	Three Months Ended March 31, 2018
Fair value, December 31, 2017	$	3,270,000
Issuances of debt		-
Accrued interest		68,125
Conversions of debt and accrued interest to shares of common stock		-
Amortization of debt issuance costs		1,250
Net unrealized gain on convertible bridge notes		(449,375	)
Fair value, March 31, 2018	$	2,890,000